All News
Rheumatic Immune-Related Adverse Events: Not Just Another IrAE
Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.
Read ArticlePegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.
Read ArticleHerpes Zoster Vaccine Update
Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.
Read ArticleRheumNow Podcast –Favorites of ACR 2019 (11.22.19)
Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.
Read ArticleMuscle Loss and Frailty in Rheumatic Disease
At the 2019 ACR annual meeting, several abstracts looked at the importance of myopia (muscle wasting due to illness at any age) and sarcopenia (age related muscle wasting) in the setting of various rheumatologic diseases.
Read ArticleACR 2019 - Report From Day 2 (Monday)
Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.
The Safety of Methotrexate
Read ArticleInfluenza Vaccine Updates And Pearls At ACR 2019
As we enter flu season it is of the utmost importance that we remember to assess our patients’ influenza vaccine status at each visit.
Read ArticlePANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
Read ArticleACR 2019 – Best of the Plenary Sessions
The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.
Read ArticleHepatitis C-Related Cryoglobulinemic Vasculitis
Flares of vasculitis can still be a problem after hepatitis C-related cryoglobulinemic vasculitis patients are cured of their hepatitis C by direct-acting antivirals, as demonstrated by data from four registries presented at ACR 2019 in Atlanta, Georgia.
Read ArticleACR 2019 - Report from Day One (Sunday)
Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one.
Delays in Diagnosis
Read ArticleMRI in the Diagnosis and Management of Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common condition seen by both primary care and in the rheumatology office.
Can the Happiest Subspecialists Experience Burnout?
The Medscape’s Physician Lifestyle & Happiness Report 2019 crowned rheumatologists as the happiest subspecialists. We topped the list with 65% of the respondents indicating that they were happy outside of work.
Read ArticleAutoinflammatory Diseases at the ACR Annual Meeting
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.
Read ArticleNew Treatments in Axial SpA from #ACR2019
There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.
Read ArticleRheumNow Podcast – ACR 2019 Round Up (11.15.19)
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.
Read ArticleRheumNow Podcast – Better Ways to Treat Gout (11.8.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleRheumNow Podcast – Ghastly, Ghoulish News (10.31.19)
Dr. Jack Cush reviews recent journal articles and info bits from the past week on RheumNow.com.
Read Article
FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
The highlight of the last day of #ACR19 is the Rheumatology Roundup Highlights #ACRBest by Drs. John Cush @RheumNow and Arthur Kavanaugh @ACRheum always worth attending with great take home messages #rheum https://t.co/eMdvc2byKG


